Community/Retail

A maternal inflammatory diet during pregnancy raises the risk of offspring developing type 1 diabetes, highlighting the impact of nutrition on early health.

Annie Eisenbeis, PharmD, MBA, showcased how Missouri’s Pharmacy Vaccine Gap Closure Program is transforming pharmacy-based immunization services through scalable workflows, team training, and a redefined role for pharmacy technicians as community health workers.

Lara Zakaria, PharmD, introduced the topic of pharmaconutrition, urging pharmacists to integrate food, lifestyle, and gut health into patient care through evidence-based, practical interventions.

Gustavo Alva, MD, a board-certified psychiatrist, discusses the importance of mental health awareness among pharmacists and patients.

By closing the gap on patients who are recommended lipid-lowering therapies but do not receive them, researchers say that thousands of cardiovascular events could be prevented and billions of dollars would be saved.

mRNA-1273, marketed as Spikevax by Moderna, is now fully approved for individuals aged 6 months through 64 years with high-risk features for severe COVID-19.

Although cholesterol-lowering guidance often touts the achievement of very low levels of low-density lipoprotein (LDL) cholesterol, emerging research demonstrates possible safety risks.

FDA approves a new dosing schedule for donanemab, enhancing safety and efficacy in treating early symptomatic Alzheimer disease.

Packed with CE sessions, interactive learning, expert insights, and a vibrant expo floor, McKesson ideaShare 2025 aims to equip independent pharmacists with the tools and strategies to elevate patient care and drive pharmacy innovation.

In a community of older adults, initiating a pneumococcal vaccination support program reduced annual pneumonia-related mortality by 25%, demonstrating broad public and individual health benefits.

The conference offers immersive, peer-driven education tracks designed to help independent pharmacies innovate, adapt, and thrive in a changing health care landscape.

Understanding RSV’s impact on respiratory and cardiovascular health underscores the importance of holistic management, prevention through vaccination, and continued innovation in treatment strategies.

Real-world studies reveal GLP-1 medications like semaglutide and tirzepatide yield less weight loss than clinical trials, highlighting treatment discontinuation challenges.

The FDA is warning of rare severe itching after stopping long-term use of popular allergy medications cetirizine and levocetirizine, urging patient education.

AI is revolutionizing pharmacovigilance by enhancing data analysis, improving patient safety, and enabling proactive risk management in drug monitoring.

The lawsuit alleges that Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. violated the law when issuing new guidance for COVID-19 vaccination.

Experts discussed the promising future of pericarditis treatment.

Funding cuts to public health agencies threaten to worsen chronic diseases and ignite infectious disease outbreaks, straining health care systems nationwide.

Y-90 resin microspheres offer a new option for patients with liver cancer for the treatment of unresectable hepatocellular carcinoma.

Andrew E. Esch, MD, MBA, discusses the need for systemic reforms to support pharmacist-led medication optimization in palliative and community-based care.

Prescription digital therapeutics (PDTs) offer scalable, accessible alternatives to traditional treatments—supporting patients, providers, and payers while addressing gaps in mental health care.

Stroke, myocardial infarction, and all-cause death were included in the composite of adverse cardiovascular events.

Six months following discharge from the hospital, adults who battled community-acquired pneumonia were at heightened risk of losing the ability to perform activities and experiencing poor quality of life.

Real-world data show that patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization.

Recent research reveals that RSV and shingles vaccines significantly lower dementia risk, highlighting the potential benefits of AS01 adjuvants in vaccination.